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Induced pluripotent stem cells (iPSCs) hold great promise for autologous cell therapies, but significant
roadblocks remain to translating iPSCs to the bedside. For example, concerns about the presumed
autologous transplantation potential of iPSCs have been raised by a recent paper demonstrating that
iPSC-derived teratomas were rejected by syngeneic hosts. Additionally, the reprogramming process can
alter genomic and epigenomic states, so a key goal at this point is to determine the clinical relevance of these
changes and minimize those that prove to be deleterious. Finally, thus far few studies have examined the
efficacy and tumorigenicity of iPSCs in clinically relevant transplantation scenarios, an essential requirement
for the FDA. We discuss potential solutions to these hurdles to provide a roadmap for iPSCs to ‘‘jump the
dish’’ and become useful therapies.The goal of stem cell-based regenerative medicine is to treat
disease states using cells, including the differentiated progeny
of pluripotent stem cells (PSCs), as the therapeutic modality. In
this way, regenerative medicine has the potential to transform
conventional medicine, which has been dominated by surgery
and drugs for centuries. The pluripotent nature of human embry-
onic stem cells (hESCs), which allows their potential use to repair
almost any tissue, is only beginning to be harnessed for human
therapies. Goldring et al. (2011) have recently reviewed safety
issues pertaining to a range of promising stem cell-based thera-
peutics, including three clinical trials using ESCs to repair nerve
cells and retinal pigment cells, which are not amenable to
replacement by adult stem cells. However, three key issues
have slowed the potential clinical use of hESCs: ethical issues,
because a human blastocyst must be used to create the lines;
immunological issues, because hESCs would be used for
allotransplants; and safety issues, because hESCs can form
teratomas and sometimes other, more malignant tumors.
When human induced pluripotent stem cells (hiPSCs) were
first reported (Takahashi et al., 2007), part of the tremendous
excitement surrounding them was their high level of similarity
to hESCs, but at the same time, iPSCs had key potential advan-
tages over hESCs. They seemed poised to avoid two out of the
three central challenges facing the clinical use of hESCs: ethical
and immune rejection issues. By using iPSCs for potential future
regenerative medicine therapies, patients could, at least in
theory, be given autologous transplants of iPSC-derived cells
without using a human blastocyst and without immunosuppres-
sive therapy. Not surprisingly, in the almost 5 years since the
initial publication on murine iPSCs (miPSCs) (Takahashi and
Yamanaka, 2006), as we have learned a great deal more about
iPSCs, clinical expectations have become more realistic. While
iPSCs are undoubtedly remarkably similar to hESCs, some
laboratories report a number of differences that cast doubt
upon the complete equivalence of the two cell types. In addition,
iPSCs have their own unique issues that present different kinds
of roadblocks to their future use in regenerative medicine thera-pies. These include the use of oncogenes for reprogramming
and the time required to produce and characterize a new iPSC
line, which may render autologous hiPSCs inherently unsuitable
to treat acute conditions such asmyocardial infarction and spinal
cord injury. Even the immune tolerance of autologous iPSCs has
recently been called into question (Zhao et al., 2011). At the same
time, the tremendous potential of iPSCs for disease modeling
has generated a great deal of excitement about iPSC-based
‘‘disease models in a dish’’ (Saha and Jaenisch, 2009). The
crucial question facing the iPSC field at this time is whether
iPSCs can escape the confines of the dish and go beyond
disease modeling to get to the clinic to more directly help
patients, as was originally hoped. Here we outline the main
hurdles facing translation of iPSCs to the bedside and discuss
the most promising solutions.
Immunity Issues
One of the most exciting aspects of the development of iPSCs
was their potential use for patient-specific autologous trans-
plants. While this remains an important potential attribute of
iPSCs and their derivatives, enthusiasm was tempered a bit
recently by the report of Zhao et al. (2011) who found that while
murine ESC (mESC)-derived teratomas were accepted by
syngeneic recipients, teratomas derived from miPSCs were
rejected with massive CD4+ T cell infiltration. What might be
the cause of this rejection in what should be a syngeneic
context? It was not a result of MYC-based reprogramming or
transgene integration, as miPSCs generated without MYC and
with nonintegrating episomal vectors also encountered a signifi-
cant immunologic response. Rather, the immunogenicity was
apparently caused by overexpression of a few specific genes
in miPSC-derived teratomas, suggesting that subtle epigenetic
changes could have important therapeutic consequences.
However, for many reasons the jury is still out on the immunity
issue. We would argue that the focus of the Zhao study only on
teratomas might very well have greatly overestimated the likeli-
hood of autologous iPSCs to elicit an immune response.Cell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc. 103
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context may confer an enhanced immunogenicity upon iPSC
derivatives that does not manifest in iPSC-derived normal
tissues. At least one of the overexpressed genes, HORMAD1,
is expressed in developing germ cells and has been character-
ized as a tumor-specific antigen (Chen et al., 2005). Its expres-
sion could therefore be a result of germ cell differentiation within
the teratoma, or a result of the tumor formation process itself,
rather than an inherent characteristic of the iPSC lines studied.
Teratoma assays require injecting large numbers of undifferenti-
ated cells, which is very different from the way the cells will be
used clinically. Indeed, there are hints that iPSCs that have
been predifferentiated in vitro do not share the immune-acti-
vating properties of teratomas. A study from the Jaenisch group
in which iPSCs were used successfully to treat sickle cell anemia
without immune rejection seems to suggest that in some circum-
stances, iPSC derivatives are not immunogenic (Hanna et al.,
2007). However, in this study the recipient mice were subjected
to both radiation and immunosuppression, making it more diffi-
cult to draw conclusions. iPSC immunogenicity is a new, critical
open question, but one that can be readily addressed by trans-
plantation of normal cells or tissues derived from miPSCs into
nonimmunodeficient, nonimmunosuppressed mice.
Because the Zhao study was only conducted in mice, another
important open question is whether similar findings would be
observed in a human context with hiPSCs. We predict that
different iPSC lines will exhibit a range of immunotolerance in
autologous hosts, so it may be fruitful to generate a panel of
hiPSC lines from each patient and test them for autologous
T cell reactivity in vitro. One potential way to begin addressing
the immune tolerance of hiPSCs and their derivatives in vivo
would be to study transplantation into mice with humanized
immune systems capable of rejecting human allografts. Human
peripheral blood mononuclear cells (PBMCs) can be used to
reconstitute the immune system of immunodeficient mice,
resulting in effective rejection of allogeneic human pancreatic
islets (Vlad et al., 2008) and skin grafts (Issa et al., 2010). A similar
experiment could be performed using hiPSCs autologous to the
PBMCs in order to detect rejection of immune-matched iPSC
grafts. It is currently unclear whether the immune capacity of
these chimeric mice is sufficiently complex to mediate rejection
of autologous iPSC derivatives that may differ only slightly from
native human tissue, but if so, the results would begin to bridge
the gap between immunologic experiments involving miPSCs in
the murine immune context and clinical trials in human patients.
We also predict that the specific tissue into which the stem cells
are transplanted may greatly influence the extent of immune
response in the recipient. Ultimately, if necessary, iPSC deriva-
tives could be given as a transplant to patients with some degree
of immunosuppression, such as the short-term leukocyte costi-
mulatory blockade reported by Pearl et al. (2011) to enhance
stem cell engraftment, but that would in some ways defeat the
purpose of using iPSCs versus ESCs.
Genome Issues
If iPSCs are to be used for therapies as we hope, wemust under-
stand the functional meaning, if any, of the different kinds of
mutations that occur in iPSC lines to define a clinically accept-
able level of genomic integrity. While some changes may be an104 Cell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc.inevitable result of extensively cultivating imperfect somatic
cells, it is critical to determine their functional impact on the
iPSCs, including any effect of mutational load on tumorigenicity,
and how any risk of deleterious mutations can be minimized.
Multiple kinds of genomic changes have been observed in
hiPSCs, which may ultimately affect the therapeutic readiness
of the cells (Figure 1). Chromosomal aneuploidy and transloca-
tions, megabase-scale duplications/deletions, and point
mutations have all been described (Gore et al., 2011; Hussein
et al., 2011; Laurent et al., 2011; Mayshar et al., 2010). As
much as these mutations are cause for concern, nonetheless
at this point there is no evidence proving or disproving that these
mutations actually matter in a functional sense.
At the level of gross chromosomal abnormalities, karyotyping
is routinely used to characterize genomic problems in hiPSCs as
well as hESCs. Alternately, when gene expression profile data
are available, these can also be used to identify chromosomal
regions of overexpression or underexpression (Mayshar et al.,
2010). These analyses point to chromosome 12 as a common
duplication in both hiPSCs and hESCs after extended culturing
(Baker et al., 2007; Mayshar et al., 2010). This chromosome
contains the pluripotency genes Nanog and GDF3 as well as
many cell cycle-related genes that may contribute to the selec-
tion of cells with these changes during culture. Duplication of
chromosome 17 was previously reported to be an aberration
specific to hESCs (Mayshar et al., 2010), but this duplication
has also recently been observed in hiPSCs (Ben-David et al.,
2011). These chromosomal anomalies are not a result of the
reprogramming method used, because gains of whole or partial
chromosomes have been identified in hiPSCs produced using
a variety of techniques including nonintegrating methods such
as synthetic mRNAs (Ben-David et al., 2011).
Karyotypes produced by G-banding can be used to detect
large-scale chromosomal abnormalities such as aneuploidy
and translocations. However, hiPSCs can also contain genomic
changes at a smaller scale, undetectable by standard karyotyp-
ing, which nonetheless could have outsized consequences for
cell biology. These smaller genetic alterations can be more
labor-intensive to identify, requiring array- or sequencing-based
high-throughput techniques. Extensive copy number variation
(CNV) has been detected in early-passage hiPSCs using
a high-resolution single nucleotide polymorphism (SNP) array.
These CNVs tend to occur in common fragile sites, indicating
that they are likely a result of replication stress (Hussein et al.,
2011). It has been reported that in some cases, high-passage
hiPSCs contain fewer CNVs than their early-passage precursors
(Hussein et al., 2011). This suggests that most reprogramming-
associated CNVs are detrimental to survival of the cells and
are selected against during culture, but further study is required.
The remaining CNVs that survive this selective pressure tend
toward deletion of tumor suppressor genes and amplification
of oncogenes (Laurent et al., 2011), highlighting the importance
of monitoring these changes in cells that are intended for thera-
peutic use.
Still smaller genomic lesions have also been identified, in-
cluding cancer-related point mutations in karyotypically normal
hiPSCs (Gore et al., 2011). Some of these point mutations exist
in the starting cell population, while the other mutations have
a less clear origin and may occur during the reprogramming
Figure 1. Genetic and Epigenetic Alterations Observed in
hiPSCs
Reprogramming can cause cells to have an abnormal karyotype
(particularly gains of chromosome 12 and 17), copy number
variation, and point mutations, all tending toward amplification/
overexpression of oncogenes and deletion/inactivation of tumor
suppressors. At the epigenetic level, reprogrammed cells can
retain a memory of the starting tissue from which they were
derived. The cells can exhibit DNA methylation defects, particu-
larly at CpG island shores, and aberrant histone modifications.
They can also vary in X chromosome inactivation status.
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these mutations occur is an important priority because this
data may shed light on not only their functional meaning, but
also on potential methods to prevent their occurrence. All of
the iPSC lines analyzed by Gore et al. were derived from fibro-
blasts, so it is quite likely that utilizing a more genomically pro-
tected cell source may minimize preexisting DNA mutations in
the starting cell population. Dermal fibroblasts are predicted to
be a relatively mutation-prone cell type given their high degree
of exposure to mutagenic UV light. It is currently unclear whether
any human somatic cell populations have significantly lessmuta-
tional load than others, although there are some hints in the liter-
ature that suggest that this is likely the case. Somatic mutation
rates in the mouse differ between organs, with higher rates of
chromosomal aberrations in peripheral blood lymphocytes
than in bone marrow (Tucker et al., 1999), and higher rates of
point mutations in small intestine than in heart (Dolle´ et al.,
2000). Mutation rates in accessible human tissues for reprog-
ramming remain to be determined, but these data from the
mouse suggest that cells from highly proliferative tissues such
as blood and small intestine may contain a higher mutational
load and therefore be less desirable as a cell source. In addition,
a tissue’s relative protection from external factors may also play
a role in the degree to which cells accumulate genetic lesions.
For example, bone marrow cells may have a lower exposure to
environmental toxins than blood or the gastrointestinal tract.CAs with CNVs, point mutations in iPSCs tend to cluster
in cancer-associated genes, possibly pointing to
connections between tumorigenic and pluripotency
programming (Knoepfler, 2009). There have been no
tumorigenicity studies comparing iPSCs with a rela-
tively large number ofmutations to lessmutated iPSCs
in a clinically relevant setting, so it is currently unclear
what an acceptable mutation rate for a PSC line may
be from a safety perspective. In addition, the potential
functional importance of specific genomic alterations
observed in iPSCs remains a key open question; it
will be important to test whether the mutational load
of iPSCs affects therapeutically relevant parameters
such as tumorigenicity, immunogenicity, and impaired
differentiation capacity. It also remains unknown if
mutational load decreases with culture time as has
been observed in at least some cases with CNVs
(Hussein et al., 2011).
The difficulty of characterizing mutations and their
effects, if any, on cellular functions illustrates the
critical importance of developing reprogrammingtechniques that preserve genomic integrity. Introduction of
reprogramming factors leads to increased DNA damage in the
form of 8-oxoguanine, which is generally caused by oxidative
stress, and histone gH2AX, a marker of double-strand breaks.
DNA damage response elements including TP53/p53,
CDKN2A/p16INK4a, and CDKN1A/p21CIP1 are also induced
(Banito et al., 2009). Cells containing preexisting DNA damage,
including irradiated cells and cells with short telomeres, tend to
undergo p53-mediated growth arrest and apoptosis when put
into reprogramming conditions (Mario´n et al., 2009). This may
be one natural antitumorigenic mechanism to limit plasticity of
cells containing DNA damage. Overriding these mechanisms
enhances reprogramming efficiency, but potentially at the cost
of allowing genetically damaged cells to be reprogrammed.
The result of such strategies may be a higher proportion of
unacceptably mutated iPSCs; indeed, Mario´n et al. (2009)
observed that while knocking down p53 increases reprogram-
ming efficiency, iPSCs produced from p53/ fibroblasts contain
more chromosomal breaks and fusions than iPSCs produced
from wild-type fibroblasts. Conversely, reprogramming technol-
ogies that enhance innate genomic protection could conceivably
produce fewer hiPSCs, but ones with fewer genomic modifica-
tions. If this speculation can be proven, it may be preferable
from a clinical perspective to use less permissive reprogramming
techniques that are designed to upregulate DNA repair
processes and/or select for cells with intact DNA. Few studiesell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc. 105
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whether their techniques allow cells with genomic changes to
be reprogrammed, especially since some smaller genomic
alterations have only been characterized in hiPSCs within the
past year (Gore et al., 2011; Laurent et al., 2011).Wewould argue
that focusing on developing methods to boost iPSC production
efficiency is not enough. Instead, the goal should be to produce
iPSCs with the fewest genomic alterations even if it is at low
efficiency; for clinical purposes, theoretically all that is needed
is a single bona fide iPSC line from a given patient.
One key way to minimize genomic damage is to exert control
over oxidative stress during reprogramming and stem cell prop-
agation. Interestingly, hiPSCs and hESCs share a similar ability
to protect against genetic damage by limiting production of reac-
tive oxygen species (ROS) and effectively clearing ROS from the
cell (Armstrong et al., 2010). Compared to differentiated cells,
partially reprogrammed cells also share genome-protective
mechanisms with fully pluripotent cells, including maintenance
of low intracellular superoxide levels and relatively few mito-
chondria (Armstrong et al., 2010). However, signs of oxidative
damage appear even earlier than these genome-protective
cellular changes, within a few days after reprogramming factor
introduction (Banito et al., 2009), suggesting that genome
protection may be amenable to enhancement especially during
the first few days of reprogramming. Culture conditions can
impact the prevalence of karyotypic abnormalities; for example,
culture at physiological (5%) oxygen tension protects cardiac
stem cells and hESCs from karyotypic changes (Li and Marba´n,
2010). Physiological oxygen tension also enhances production
of iPSCs compared with either normoxic (21%) or hypoxic
(1%) conditions, increasing the efficiency and rate of reprogram-
ming murine and human fibroblasts (Yoshida et al., 2009).
However, iPSCs produced in 5% oxygen conditions have just
as many point mutations as those produced at atmospheric
oxygen (Gore et al., 2011), so it is still unclear whether hypoxic
culture actually imparts any genomic protection during reprog-
ramming. To mimic the effect of hypoxia, simply adding more
antioxidants to the culture medium would seem like a plausible
way to protect the genome. However, while addition of the anti-
oxidant Vitamin C to culture medium has been reported to
enhance reprogramming efficiency (Esteban et al., 2010), exces-
sive antioxidant concentrations could actually increase the prev-
alence of genomic damage in stem cells by inhibiting DNA repair
(Li andMarba´n, 2010). A comprehensive study of genomic integ-
rity of iPSCs produced at varied oxygen tension and antioxidant
concentrations would help identify optimal conditions to reduce
ROS damage while maintaining endogenous DNA repair at
a high level.
Other methods of minimizing reprogramming-induced oxida-
tive stress remain to be explored. These include ROS-limiting
culture conditions known to enhance hESC pluripotency, such
as reduced glucose levels in media (Crespo et al., 2010) or the
addition of small molecule inhibitors of oxidative phosphorylation
(Varum et al., 2009). Additionally, two hiPSC lines were reported
to have lower expression levels of the antioxidant genes SOD2
and GSR compared with hESCs (Armstrong et al., 2010), sug-
gesting the possibility that exogenously expressing these antiox-
idant genes during reprogramming may provide more ESC-like
protection from oxidative damage. While the molecular mecha-106 Cell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc.nisms underlying reprogramming-associated DNA damage
and repair are still being investigated, protecting the genome
is clearly a critical and promising element of emerging cellular
reprogramming strategies intended for clinical use. The impor-
tance of preserving genomic integrity has been a consideration
from the very beginning of the iPSC field, as exemplified by
the focus on removing MYC, a factor known to induce genomic
instability (Felsher and Bishop, 1999). The relatively new data
on mutations in iPSCs, including those produced in the absence
of MYC, reinforce the potential importance of exploring innova-
tive new approaches to genome preservation.
Epigenome Issues
Cellular reprogramming to pluripotency represents a herculean
feat of epigenomic reorganization from a fully differentiated cell
into an embryonic stem-like cell. The reprogrammed chromatin
state is characterized at least in part by bivalent domains
containing both transcriptionally activating (3meK4-H3) and
repressive (3meK27) histone marks creating a poised gene state
(Guenther et al., 2010), a state also observed in ESCs (Bernstein
et al., 2006). DNA methylation also has to be reprogrammed
across the genome, from a somatic cell state in which essentially
all methylation occurs at CpG dinucleotides to a pluripotent state
in which non-CpG sites account for 20%–30% of global DNA
methylation (Lister et al., 2011). Not surprisingly, sometimes
epigenomic reprogramming appears to be incomplete in iPSCs,
especially at early passages soon after derivation (Lister et al.,
2011; Pick et al., 2009; Polo et al., 2010; Stadtfeld et al., 2010).
Several epigenetic differences between hiPSCs and hESCs
have been described (Figure 1); however, it is unknown what
effect these differences may have on differentiation or tumorige-
nicity of the cells. For example, differences in X chromosome
inactivation (XCI) status have been described between different
female hiPSC lines, usually with the implication that the best
hiPSCs would have two active X chromosomes like their murine
counterparts (Tchieu et al., 2010). Both hESC and hiPSC lines
show heterogeneous XCI (Bruck and Benvenisty, 2011), which
can be a dynamic process that changes with time in culture
(Kiedrowski et al., 2011). In particular, derivation of hESCs in
physiological (5%) oxygen conditions allows the production of
cells with two active X chromosomes, while standard normoxic
culture can induce irreversible XCI in these cells (Lengner
et al., 2010). It is currently unclear whether these differences in
XCI have any relation to the clinical safety and efficacy of the
cells. It is hypothetically possible that hiPSCs that retain the
XCI status of the parental fibroblasts may actually be safer
because they avoid the possibility of aberrant X chromosome
activation in their differentiated progeny, which is commonly
seen in malignancies.
In addition to differences in XCI status, variation in imprinted
gene expression has also attracted attention. Aberrant silencing
of imprinted genes in miPSCs has been reported, which hinders
the cells’ ability to contribute to chimeric mice (Stadtfeld et al.,
2010). These differences may not ultimately impact the clinical
utility of iPSCs if the imprinted gene products are not critical to
the function of the cells’ differentiated progeny; however, proper
expression of imprinted genes is critical during development of
clinically relevant tissues such as the nervous system, suggest-
ing that these genes may also be important during in vitro
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is the fact that some hiPSC lines overexpress cancer-associated
imprinted genes (Pick et al., 2009). Based on the very limited
data available, imprinting errors may turn out to be relatively
rare events in hiPSCs, so screening a few cell lines for imprinted
gene expression may be sufficient to identify correctly imprinted
cells suitable for transplantation.
During reprogramming, DNA methylation patterns are
massively altered to be remarkably similar, but not identical, to
that of ESCs. Differential CpG methylation between iPSCs and
ESCs falls roughly equally into two categories: (1) methylation
patterns found in the iPSC parental cells, indicating epigenetic
memory, and (2) methylation patterns specific to iPSCs that
are found neither in ESCs nor the starting cells, many of which
are shared among several independent iPSC lines (Lister et al.,
2011). At least one common incompletely reprogrammed gene,
C9orf64, appears to play a functional role in reprogramming,
as RNAi ablation of this gene reduces reprogramming efficiency
(Ohi et al., 2011). Differential methylation of CpG island shores
appears to be a major way in which reprogramming alters the
epigenetic landscape of cells (Doi et al., 2009). DNA methylation
patterns in low-passage miPSCs retain a memory of the starting
tissue, resulting in impaired differentiation toward unrelated
lineages; differences in overall gene expression, methylation,
and differentiation capacity between miPSCs derived from
different tissues are subsequently eliminated by passage 16
(Polo et al., 2010). Incompletely reprogrammed genes tend to
be isolated from other genes that are silenced during reprogram-
ming, indicating that these early-passage differences may occur
because isolated genes recruit silencing machinery less
effectively (Ohi et al., 2011). However, some aberrant CG and
non-CG methylation persists in hiPSCs even up to passage 65
and is retained after differentiation (Lister et al., 2011), suggest-
ing that any abnormal gene expression resulting from imperfect
reprogramming could persist even in the differentiated cell
product. While epigenetic memory could be a hazard, it also
has the potential to be useful. If epigenetic memory could be
harnessed and maintained during long-term culture rather than
obliterated, iPSCs could potentially be used to generate differen-
tiated cell populations with greater ease and possibly greater
purity than could be derived from ESCs. For example, hiPSCs
derived from pancreatic islet beta cells show enhanced differen-
tiation into insulin-producing cells compared with hESCs or
hiPSCs derived from other cell types, even after moderate
passaging (passage 10–20) in culture (Nur et al., 2011).
Rewriting histone modifications is a critical element of cellular
reprogramming, as indicated by the plethora of small molecule
reprogramming enhancers that act on chromatin-modifying
enzymes that target histones. The reprogramming oncogene
MYC also regulates global chromatin structure through its
interaction with histone-modifying complexes including histone
acetyltransferases (Knoepfler et al., 2006). This global effect of
MYC may, in fact, be just as critical for enhancing reprogram-
ming as its role as a classical transcription factor through which
MYC contributes to maintenance and induction of pluripotency
by repressing differentiation-associated gene expression (Smith
et al., 2010; Varlakhanova et al., 2010). Reprogramming of
human cells is enhanced by small-molecule histone deacetylase
(HDAC) inhibitors such as valproic acid (Huangfu et al., 2008)and sodium butyrate (Mali et al., 2010), which facilitate chromatin
remodeling events such as histone H3 lysine 9 acetylation.
Inhibition of the G9a histone methyltransferase by BIX-01294
synergizes with sodium butyrate to reprogram human cells
(Mali et al., 2010), likely by promoting an active chromatin state
characterized by decreased histone methylation and increased
acetylation. However, HDAC inhibitors have also been reported
to induce double-strand breaks in DNA (Lee et al., 2010), so it
remains to be determined whether these molecules themselves
may induce karyotype abnormalities or other DNA sequence
changes. More generally, it is assumed from the perspective of
iPSC formation that small molecules such as HDAC inhibitors
are either helpful or neutral, when the reality may be far more
complex and could include deleterious effects.
How might a pluripotent epigenome be induced and pre-
served? Some of the epigenetic differences between hESCs
and hiPSCs may reflect memory of the hiPSC parental tissue.
However, some differences are almost certainly a result of the
reprogramming process, since the use of isolated transcription
factors is inherently quite different from generation of hESCs,
which are derived from pluripotent ESCs that have yet to narrow
their differentiation potential. It is possible that some of the
epigenomic drugs such as those already used in iPSC produc-
tion may have beneficial effects by preserving genomic integrity.
The use of chromatin-modifying enzyme genes as reprogram-
ming factors may lower the efficiency of iPSC production but
give the bonus of producing iPSCs with fewer changes in their
epigenomes. This important concept remains largely unad-
dressed in the field. Another possibility for producing iPSCs
with more completely reprogrammed epigenomes is the use of
miRNAs for reprogramming. Because of their pleiotropic func-
tion in rapidly regulating hundreds of mRNAs, reprogramming
with miRNAs could potentially establish an ESC-like phenotype
and epigenome more rapidly and completely than reprogram-
ming with transcription factors. For example, the miRNA cluster
miR302/367, which is strongly upregulated in hESCs compared
with nonpluripotent cells (Laurent et al., 2008), is capable of
rapidly reprogramming human fibroblasts to pluripotency in the
absence of any exogenous transcription factors (Anokye-Danso
et al., 2011; Miyoshi et al., 2011). These studies of miRNA-based
reprogramming did not report any epigenomic information about
the iPSC lines, so we look forward to an analysis of the rate of
epigenomic aberrations in these cells compared with cells
reprogrammed via transcription factors.
Tumorigenicity
The current gold standard test of pluripotency for hiPSCs and
hESCs is teratoma formation (Mu¨ller et al., 2010), which is inher-
ently a tumorigenesis assay. However, large numbers of undif-
ferentiated cells implanted into an immunodeficientmouse bears
little relevance to the in vivo environment that the cells or their
differentiated derivatives will encounter in clinical use. In addition
to teratoma assays, it will be vital to test the tumorigenicity of
hiPSCs in more clinically relevant transplantation scenarios.
Teratoma assays as commonly conducted in the stem cell field
at present unfortunately have very little relevance to the tumori-
genic potential of iPSCs in the context of human regenerative
medicine therapies. The ideal preclinical tumorigenicity assay
would be quite different from teratoma assays in that it wouldCell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc. 107
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tissue of interest (e.g., injection into brain rather than subcuta-
neous or kidney capsule injection), the use of immunocompetent
recipient mice—perhaps with the kind of transient immunosup-
pressive drug regimen used in human recipients, and rigorous
assays for the presence of human cells (e.g., by qPCR for Alu
repeats) at off-target organ sites. These three study components
are all of high importance to the FDA, which is by comparison
relatively uninterested in the ability of potential stem cell-based
drugs to form teratomas in classical teratoma assays. The impor-
tance of such studies is illustrated by the fact that biotechnology
companies currently in Phase I or Phase I/II trials for hESC-based
therapies, as well as those conducting preclinical studies leading
up to future Phase I trials, currently conduct such clinically
relevant studies, often at the request of the FDA.
Preclinical testing of hiPSCs must therefore include clinically
relevant transplantation scenarios that recapitulate the microen-
vironment cells will encounter in vivo, of which a few examples
exist in the literature. Mesenchymal stem cells derived from
hiPSCs engraft and induce functional improvement in a mouse
hind limb ischemia model (Lian et al., 2010); the 21-day duration
of transplantation follow-up is too short to assess tumorigenicity,
but in separate assays, the cells did not exhibit teratoma-forming
capacity after differentiation. Tsuji et al. (2010) classified miPSC
lines as ‘‘safe’’ or ‘‘unsafe’’ based on residual teratoma forming
capacity of neurospheres derived from the cells. This preselec-
tion step was sufficient to identify specific iPSC clones whose
differentiated progeny engraft in injured murine spinal cord,
participate in remyelination, and improve locomotor function
without tumor formation. Of note, although one ‘‘unsafe’’ iPSC
line did not produce teratomas in mouse spinal cord, it did
produce clusters of Nanog+ cells; this highlights the importance
of analyzing mice for other signs of tumorigenesis in addition to
teratoma formation. It is not widely appreciated that hESCs also
have been shown to have the potential, albeit somewhat limited,
to form tumors beyond teratomas, including malignant tumors in
SCID mice bearing engrafted human fetal tissue (Shih et al.,
2007). Hepatic progenitors differentiated from retrovirus-derived
human iPSCs were shown to engraft and regenerate cirrhotic
mouse liver, with no evidence of tumor formation after a relatively
lengthy 7 month follow-up (Liu et al., 2011). This lack of tumori-
genicity may be partly due to efficient (>90%) differentiation to
hepatic lineages; however, the study used intravenous injection
(a method that lead to substantial cell loss in the lung) of an
already relatively low number of cells (0.1–2 3 106 per mouse),
so the lack of tumors may also be due to the delocalized route
of administration and minimal effective cell dose. Swistowski
et al. (2010) found that hiPSC-derived dopaminergic neurons
engraft and improve function in a rat model of Parkinson’s
disease with no evidence of teratoma formation at 12 weeks.
A similar study of hiPSCs using a different differentiation protocol
found proliferative nestin+ precursor cells in the rat brain
(Cai et al., 2010), suggesting that the degree of differentiation
achieved before transplantation may be a critical variable and
that partially differentiated iPSC-derived progenitor cells could
still form nonteratoma tumors if their proliferation is uncontrolled.
Much research has focused on removing or replacing the
potent oncogene MYC in reprogramming in an effort to reduce
tumorigenicity. MYC can be omitted or replaced by small108 Cell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc.molecules that target chromatin-modifying proteins and/or
signaling pathways, yielding satisfactory levels of reprogram-
ming. Substituting the MYCL1/L-Myc isoform is reported to
reduce tumor formation in miPSC-derived chimeric mice (Naka-
gawa et al., 2010). Complicating the matter, endogenous MYC
clearly also plays a role in iPSCs, repressing differentiation
toward endodermal lineages inmiPSCs at least in part by repres-
sing expression of Gata6 (Smith et al., 2010). However, MYC is
just the tip of the oncogenic iceberg. All known reprogram-
ming-inducing genetic factors also have links to cancer, many
of which are still being elucidated. KLF4 can function as either
an oncogene (Wei et al., 2010) or a tumor suppressor (Zhao
et al., 2004) in human cancers, depending on the cellular context.
LIN28 contributes to a variety of human cancers by repressing
expression of the let-7 family of miRNAs (Viswanathan et al.,
2009). SOX2 functions as a potent oncogene in breast (Chen
et al., 2008), lung, and esophageal cancers (Bass et al., 2009),
while aberrant POU5F1 expression has been observed in
osteosarcoma (Gibbs et al., 2005) and pancreatic cancer (Wen
et al., 2010). Nanog is overexpressed in germ cell tumors
(Hoei-Hansen et al., 2005), and its expression correlates with
pathological grade in ovarian cancer (Pan et al., 2010). The
miRNA clustermiR302/367 is overexpressed in germ cell tumors
(Murray et al., 2010) and increases the growth of hESC-derived
teratomas (Barroso-delJesus et al., 2011), suggesting an onco-
genic role.
Concern has been raised about using integrated viral vectors
to generate hiPSCs destined for the clinic, due to the possibility
of insertional mutagenesis and reactivation of silenced re-
programming factors upon differentiation. To address this issue,
several nonintegrating reprogramming techniques have been
reported, including the use of episomal vectors (Yu et al.,
2009), proteins (Kim et al., 2009), mRNAs (Warren et al., 2010),
and miRNAs (Anokye-Danso et al., 2011). However, even
transient overexpression of these oncogenes may produce
lasting tumorigenic changes in the cells if they cause genomic
instability. These potential problems may not be analogous to
any process that occurs during hESC derivation. Consequently,
rigorous preclinical testing is vital to the future success of iPSC-
based therapies.
Conclusions
Thus far, much of the focus in the iPSC field has been on devel-
oping themost efficient methods for making iPSCs from a variety
of parental cells, including those from patients who exhibit
specific disease states. We argue for a shift in priorities. Future
studies of hiPSCs should increase focus on issues most relevant
to eventual clinical use of the cells, such as understanding the
potential immunogenicity of autologous transplants, preserving
genomic and epigenomic integrity during cellular reprogram-
ming, and addressing tumorigenicity using clinically relevant
transplantation protocols and not just teratoma assays. Key to
this process will be two major goals: (1) studying the functional
meaning of the genomic and epigenomic alterations described
herein to define acceptable levels of changes, and (2) developing
more rapid, accurate methods to screen iPSC lines for poten-
tially unacceptable abnormalities. High-throughput techniques
including microarray analysis to detect aberrant gene expres-
sion, SNP genotyping and comparative genomic hybridization
Cell Stem Cell
Perspectiveto detect copy number changes associated with tumorigenicity,
and resequencing of cancer-related genes to detect point
mutations may be necessary to characterize iPSC lines for clin-
ical use. Functional assays such as transplantation in an animal
model, whether teratoma assays or, preferably, a more clinically
relevant transplantation scenario, are other, more direct possible
approaches to characterize the tumorigenic potential of a stem
cell line.While molecular diagnostics alone do not have sufficient
predictive power to be used as stand-alone tools for evaluation
of tumorigenicity or metastatic potential of stem cell lines, they
are rapidly evolving and may have substantial benefit when
combined with other, more functional assays. More information
could also be extracted from existing assays; for example,
putative teratomas could be stained for markers of proliferation
and pluripotency to quantify remaining levels of undifferentiated,
highly proliferative cells possibly indicative of higher tumorigenic
risk. However, all of these assays must be validated using
clinically meaningful endpoints; for therapeutic purposes,
a ‘‘healthy’’ iPSC will be defined by its capacity to generate
functional differentiated cells with minimal risk of tumorigenesis
or immunogenicity.
A broad study of the rate and nature of genomic abnormalities
in hiPSCs produced by various reprogramming techniques
(including the suggestions herein for preserving genomic and
epigenomic integrity) would resolve questions related to the
ability of these methods to preserve genomic integrity and/or
select for cells with intact genomes. Taking these approaches
may give iPSCs a boost in their trajectory, which has plateaued
of late, to ‘‘jump the dish’’ and get into the clinic.
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